Transaction Overview
CanSino Biologics Inc. (Stock code: 6185.HK) successfully listed on the Hong Kong Stock Exchange on March 28, 2019. CMBI acts as Joint Bookrunner and Joint Lead Manager for this IPO.
CanSino’s mission is to develop, manufacture and commercialize high quality, innovative and affordable vaccines. The company issued 57,248,600 H shares (100% new shares), accounting for 26.24% of the total issued share capital before the exercise of the over-allotment option. The offering price is set at HK$22.00, and the offering amount is approximately US$160 million (Pre-shoe).
Cansino’s IPO has been widely recognized by investors. Both of International offering and HKPO have been significantly oversubscribed. Company finally achieved high end pricing at HK$22.00. Aggregate amount of cornerstone investment accounts for 28.04% of the base offer size, including Orbimed, Tsinlien Zhuo Rui (Tianjin Goverment) and LAV Amber Limited. In the case of extremely volatile market, this IPO is still welcomed by domestic and foreign investors. This achievement was strongly supported by various departments and local branch offices of the parent company CMB. The close cooperation among Corporate Finance, Equity Capital Markets, Asset Management Department, Equity Department, Wealth Management Department, Legal & Compliance Department, Operation Department and other departments helps a lot, which lays an important foundation for the final pricing of the project. The important contribution of CMBI to the project during its issuance and offering has been highly recognized by the management of the company.
Source: Company Announcement
About CanSino
CanSino’s mission is to develop, manufacture and commercialize high quality, innovative and affordable vaccines. Its mission is being fulfilled by an accomplished team of founders and senior management – world-class scientists with a record of leading the development of innovative international vaccines at global pharmaceutical companies such as Sanofi Pasteur, AstraZeneca and Wyeth (now Pfizer). Other management members are also vaccine industry veterans from leading multi-national and domestic biologics companies.
1、Its vaccine pipeline, which is strategically designed to address China’s vast and underserved market, can be summarized into three categories: (i) globally innovative vaccines to serve China’s unmet medical needs (such as Ad5-EBOV, its TB Booster candidate and its PBPV candidate); (ii) potential first-in-class vaccines in China developed to replace the current primary vaccines with higher-quality world-class vaccines (such as its DTcP vaccine candidates and MCV4 candidate); and (iii) potential best-in-class vaccines in China developed to compete with the imported products in the PRC market (such as its PCV13i candidate).
2、The Company is developing 15 vaccine candidates for 12 disease areas. In addition to its three near-commercial assets covering meningococcal diseases and Ebola virus disease, it has six vaccine candidates in clinical trial stage or CTA stage. The Company also has six pre-clinical vaccine candidates, including one combination vaccine candidate
Source: Prospectus, Company’s HKEX Deal Announcements, Dealogic
